Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3927-3933

  North, Thomas W ^a,b,c   Villalobos, Andradi ^a   Hurwitz, Selwyn J ^a,b   Deere, Jesse D ^c   Higgins, Joanne ^c   Chatterjee, Payel ^a,b   Tao, Sijia ^a,b   Kauffman, Robert C ^c   Luciw, Paul A ^c   Kohler, James J ^a   Schinazi, Raymond F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMDOXOVIR; DNA; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASE; INTEGRASE INHIBITOR; L 870 812; RNA; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; VIRUS RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INOCULATION; KINETICS; LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA; PRECURSOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TANDEM MASS SPECTROMETRY; VIREMIA; VIRUS INFECTION; VIRUS LOAD; ANIMAL; BLOOD; DRUG COMBINATION; PROCEDURES; RECURRENT DISEASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COMBINATIONS; KINETICS; MACACA MULATTA; RECURRENCE; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84903151095     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02522-14     Document Type: Article

References (43)

1. Schinazi RF, Cannon DL, Arnold BH, Martino-Saltzman D. 1988. Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 32:1784-1787. http://dx.doi.org/10.1128/AAC.32.12.1784.
2. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF. 2004. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr. Top. Med. Chem. 4:895-919. http://dx.doi.org/10.2174/ 1568026043388484.
3. Humphreys EH, Chang LW, Harris J. 16 June 2010. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst. Rev. http://dx.doi.org/10.1002/14651858.CD006517.pub3.
4. McKinnon JE, Mellors JW, Swindells S. 2009. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir. Ther. 14:1-12.
5. Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-U. S. A. panel. JAMA 300:555-570. http://dx.doi.org/10.1001/jama.300.5.555.
6. De Clercq E. 2010. Antiretroviral drugs. Curr. Opin. Pharmacol. 10:507-515. http://dx.doi.org/10.1016/j.coph.2010.04.011.
7. Chun TW, Davey RT, Jr, Engel D, Lane HC, Fauci AS. 1999. Reemergence of HIV after stopping therapy. Nature 401:874-875. http://dx.doi.org/10.1038/44755.
8. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. 2002. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J. Acquir. Immune Defic. Syndr. 31(Suppl 3):S112-S117. http://dx.doi.org/10.1097/00126334-200212153-00005. (Pubitemid 35453569)
9. Costiniuk CT, Kovacs C, Routy JP, Singer J, Gurunathan S, Sekaly RP, Angel JB. 2013. Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res. Hum. Retroviruses 29:266-269. http://dx.doi.org/10.1089/AID.2011.0343.
10. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884. http://dx.doi.org/10.1073/pnas.0800050105. (Pubitemid 351723493)
11. Chun TW, Fauci AS. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U. S. A. 96:10958-10961. http://dx.doi.org/10.1073/pnas.96.20.10958. (Pubitemid 29487311)
12. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480. http://dx.doi.org/10.1056/NEJM200102153440702. (Pubitemid 32164898)
13. Weed MR, Steward DJ. 2005. Neuropsychopathology in the SIV/macaque model of AIDS. Front. Biosci. 10:710-727. http://dx.doi.org/10.2741/1566.
14. Ansari AA, Mayne AE, Onlamoon N, Pattanapanyasat K, Mori K, Villinger F. 2004. Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS. Immunol. Res. 29:1-18. http://dx.doi.org/10.1385/IR:29:1-3:001.
15. Rausch DM, Murray EA, Eiden LE. 1999. The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. J. Leukoc. Biol. 65:466-474. (Pubitemid 29160174)
16. Deere JD, Schinazi RF, North TW. 2011. Simian immunodeficiency virus macaque models of HIV latency. Curr. Opin. HIV AIDS 6:57-61. http://dx.doi.org/10.1097/COH.0b013e32834086ce.
17. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu SL, Lifson JD, KewalRamani VN, Mellors JW, Coffin JM, Ambrose Z. 2011. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J. Virol. 85:1067-1076. http://dx.doi.org/10.1128/JVI.01701-10.
18. North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF. 2005. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J. Virol. 79:7349-7354. http://dx.doi.org/10.1128/JVI.79.12.7349-7354.2005. (Pubitemid 40756770)
19. Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. 2007. HIV/AIDS: in search of an animal model. Trends Biotechnol. 25:333-337. http://dx.doi.org/10.1016/j.tibtech.2007.05.004.
20. Hatziioannou T, Ambrose Z, Chung NP, Piatak M, Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD. 2009. A macaque model of HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 106:4425-4429. http://dx.doi.org/10. 1073/pnas.0812587106.
21. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B. 1995. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 92:8210-8214. http://dx.doi.org/10. 1073/pnas.92.18.8210.
22. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, Uberla K. 1995. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun. 211:850-856. http://dx.doi.org/10.1006/bbrc.1995. 1890.
23. Giuffre AC, Higgins J, Buckheit RW, Jr., North TW. 2003. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob. Agents Chemother. 47:1756-1759. http://dx.doi.org/10.1128/AAC.47.5.1756-1759.2003. (Pubitemid 36548569)
24. Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW. 2004. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:3483-3490.http://dx.doi.org/10.1128/AAC.48.9.3483-3490.2004. (Pubitemid 39129349)
25. Durand CM, Blankson JN, Siliciano RF. 2012. Developing strategies for HIV-1 eradication. Trends Immunol. 33:554-562. http://dx.doi.org/10.1016/j.it. 2012.07.001.
26. Lewin SR, Rouzioux C. 2011. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25:885-897. http://dx.doi.org/10.1097/QAD.0b013e3283467041.
27. Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander L. 2002. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 76:5803-5806. http://dx.doi.org/10.1128/JVI.76.11.5803-5806.2002. (Pubitemid 34517931)
28. Marthas ML, Ramos RA, Lohman BL, Van Rompay KK, Unger RE, Miller CJ, Banapour B, Pedersen NC, Luciw PA. 1993. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J. Virol. 67:6047-6055. (Pubitemid 23277515)
29. Deere JD, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E, Schinazi RF, Luciw PA, North TW. 2010. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One 5:e11640. http://dx.doi.org/10.1371/journal.pone.0011640.
30. Cretton EM, Schinazi RF, McClure HM, Anderson DC, Sommadossi JP. 1991. Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob. Agents Chemother. 35:801-807. http://dx.doi.org/10.1128/AAC.35.5.801.
31. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N. 2008. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob. Agents Chemother. 52:3144-3160. http://dx.doi.org/10.1128/AAC.00350-08.
32. Boudinot FD, Schinazi RF, Gallo JM, McClure HM, Anderson DC, Doshi KJ, Kambhampathi PC, Chu CK. 1990. 3′-Azido-2′,3′-dideoxyuridine (AzddU): comparative pharmacokinetics with 3′-azido-3′- deoxythymidine (AZT) in monkeys. AIDS Res. Hum. Retroviruses 6:219-228. http://dx.doi.org/10.1089/aid.1990.6.219. (Pubitemid 20116112)
33. Lopez-Anaya A, Unadkat JD, Schumann LA, Smith AL. 1990. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J. Acquir. Immune Defic. Syndr. 3:1052-1058. (Pubitemid 20373633)
34. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW. 2004. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532. http://dx.doi.org/10.1126/ science.1098632. (Pubitemid 38971345)
35. Leutenegger CM, Higgins J, Matthews TB, Tarantal AF, Luciw PA, Pedersen NC, North TW. 2001. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res. Hum. Retroviruses 17:243-251. http://dx.doi.org/10.1089/088922201750063160. (Pubitemid 32113572)
36. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. http://dx.doi.org/10.1038/387188a0. (Pubitemid 27209434)
37. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA. 2010. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84:2913-2922. http://dx.doi.org/10.1128/JVI.02356-09.
38. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA. 2007. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315-2321. http://dx.doi.org/10.1097/QAD.0b013e3282f12377. (Pubitemid 350287458)
39. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517. http://dx.doi.org/10. 1038/8394. (Pubitemid 29220209)
40. Markowitz M, Evering TH, Garmon D, Caskey M, La Mar M, Rodriguez K, Sahi V, Palmer S, Prada N, Mohri H. 21 January 2014. A randomized open-label study of three- versus five-drug combination antiretroviral therapy in newly HIV-1 infected individuals. J. Acquir. Immune Defic. Syndr.
41. Apetrei C, Pandrea I, Mellors JW. 2012. Nonhuman primate models for HIV cure research. PLoS Pathog. 8:e1002892. http://dx.doi.org/10.1371/journal.ppat. 1002892.
42. Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A. 2012. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog. 8:e1002774. http://dx.doi.org/10.1371/journal.ppat.1002774.
43. Kline C, Ndjomou J, Franks T, Kiser R, Coalter V, Smedley J, Piatak M, Jr, Mellors JW, Lifson JD, Ambrose Z. 2013. Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One 8:e84275. http://dx.doi.org/10.1371/journal.pone.0084275.